



ARTICLE

OVERCOMING CHALLENGES FOR INHALED DRUG DEVELOPMENT

Abstract

Inhaled biologics have been forecast to grow in importance due to the fact that inhalation presents a highly attractive route for the administration of various classes of large molecule, particularly for the treatment of respiratory diseases.

In this article, Chris Vernal, Business Development Director, Intertek Pharmaceutical Services, discusses the significance and difficulties of biologics in the inhalables sector, and how Intertek's Centre of Excellence for Inhaled and Nasal Biologics provides valuable services for those developing products in this area.

Click the button below to download the full article.

DOWNLOAD ARTICLE